Ismaya W T, Efthyani A, Retnoningrum D S, Lai X, Dijkstra B W, Tjandrawinata R R, Rachmawati H
a Dexa Laboratories of Biomolecular Sciences , JABABEKA II Industrial Estate , Cikarang.
b Research group of Pharmaceutics, School of Pharmacy , Bandung Institute of Technology , Bandung.
Biotech Histochem. 2017;92(6):411-416. doi: 10.1080/10520295.2017.1339912. Epub 2017 Aug 11.
The light subunit of mushroom, Agaricus bisporus, tyrosinase (LSMT), has been identified as an extrinsic component of the enzyme. Its function is unknown, but it can cross an epithelial cell layer, which suggests that it can be absorbed by the intestine. A similar capability has been demonstrated for the HA-33 component of the progenitor toxin from Clostridium botulinum, which is the closest structural homolog of LSMT. Unlike HA-33, LSMT appears to be non-immunogenic as shown by preliminary tests in Swiss Webster mice. We investigated the immunogenicity and histopathology of LSMT in mice to determine its safety in vivo. LSMT did not evoke generation of antibodies after prolonged periods of intraperitoneal administration. Histopathological observations confirmed the absence of responses in organs after twelve weekly administrations of LSMT. We found that LSMT is not toxic and is less immunogenic than the C. botulinum HA-33 protein, which supports further research and development for pharmaceutical application.
双孢蘑菇酪氨酸酶的轻亚基(LSMT)已被鉴定为该酶的一种外在成分。其功能尚不清楚,但它能够穿过上皮细胞层,这表明它可以被肠道吸收。肉毒梭菌祖毒素的HA-33成分也具有类似能力,该成分是与LSMT结构最相似的同源物。与HA-33不同,初步的瑞士韦伯斯特小鼠试验表明,LSMT似乎不具有免疫原性。我们研究了LSMT在小鼠体内的免疫原性和组织病理学,以确定其体内安全性。长时间腹腔注射LSMT后,未引发抗体产生。组织病理学观察证实,每周注射LSMT十二次后,各器官均无反应。我们发现,LSMT无毒,且免疫原性低于肉毒梭菌HA-33蛋白,这为其药物应用的进一步研发提供了支持。